Aesthetic plastic surgery · 2025
Injection of the Concentrate Derived from Nanofat Graft Promotes Hair Growth in Patients of Male Androgenetic Alopecia: A Clinical Pilot Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Zhidan, Chen Nan, Xiao Liling, Li Kecheng, Liu Hongwei
Аннотация
BACKGROUND: Androgenetic alopecia (AGA) is the most common hair loss disorder in men. Adipose-derived stem cells (ADSCs) have shown regenerative potential, but their clinical application is hindered by complex processing. Concentrate derived from nanofat graft (CDNF), rich in ADSCs, promotes hair growth in mice, suggesting its potential clinical efficacy.
OBJECTIVE: This study aimed to assess the efficacy of intradermal CDNF injection as a novel autologous therapeutic approach for AGA.
METHODS: Ten male AGA patients (Norwood-Hamilton III-VI, aged 22-38) received three CDNF injections (0.25ml/cm2) into the scalp subdermis at 4-week intervals. Changes in hair density, diameter, and pigmentation were evaluated via ultra-high-resolution photography at baseline, 3, 6, and 12 months post-treatment.
RESULTS: All patients exhibited hair regeneration at all follow-ups. Significant improvements were observed not only in total hair count but also in hair diameter and pigmentation. Quantitative analysis revealed a significant increase in the number of hairs with a diameter >0.03 mm at all follow-up time points. Conversely, the number of hairs with a diameter ≤0.03 mm demonstrated a notable decrease at the 3- and 6-month assessments. Peak efficacy was observed at 12 months post-injection, with total hair counts significantly exceeding baseline levels. No severe adverse events were reported. Furthermore, treatment outcomes showed no significant variation with patient age.
CONCLUSIONS: Intradermal CDNF injection is an efficacious and safe regenerative therapy for male AGA, suggesting that this regenerative therapy may serve as a promising alternative treatment option for hair loss.
LEVEL OF EVIDENCE II: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
OBJECTIVE: This study aimed to assess the efficacy of intradermal CDNF injection as a novel autologous therapeutic approach for AGA.
METHODS: Ten male AGA patients (Norwood-Hamilton III-VI, aged 22-38) received three CDNF injections (0.25ml/cm2) into the scalp subdermis at 4-week intervals. Changes in hair density, diameter, and pigmentation were evaluated via ultra-high-resolution photography at baseline, 3, 6, and 12 months post-treatment.
RESULTS: All patients exhibited hair regeneration at all follow-ups. Significant improvements were observed not only in total hair count but also in hair diameter and pigmentation. Quantitative analysis revealed a significant increase in the number of hairs with a diameter >0.03 mm at all follow-up time points. Conversely, the number of hairs with a diameter ≤0.03 mm demonstrated a notable decrease at the 3- and 6-month assessments. Peak efficacy was observed at 12 months post-injection, with total hair counts significantly exceeding baseline levels. No severe adverse events were reported. Furthermore, treatment outcomes showed no significant variation with patient age.
CONCLUSIONS: Intradermal CDNF injection is an efficacious and safe regenerative therapy for male AGA, suggesting that this regenerative therapy may serve as a promising alternative treatment option for hair loss.
LEVEL OF EVIDENCE II: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.